Ed Silverman
Senior Writer at STAT
Columnist at Pharmalot Newsletter
Pharmalot columnist and senior writer at @STATnews.. former WSJer.. proud dad; likes music, dogs and taking naps
Articles
-
1 week ago |
statnews.com | Ed Silverman
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to catch up on our reading, promenade with the official mascots and escort Mrs. Pharmalot to a soiree. We hope to find time for another listening party, where the rotation will likely include this, this, this, this and this. And what about you?
-
1 week ago |
statnews.com | Ed Silverman
Now that Gilead Sciences has won U.S. regulatory approval for its groundbreaking HIV prevention drug, the company has another hurdle to clear — ensuring the medicine can be accessed in low-income countries where the disease remains a stubborn problem. As far as Gilead is concerned, the groundwork exists to meet that goal. Last October, the drugmaker reached voluntary licensing agreements to eventually make lenacapavir available in 120 mostly low- and lower-middle-income countries.
-
1 week ago |
statnews.com | Jason Mast |Ed Silverman
The Food and Drug Administration approved Wednesday a powerful new drug that provides nearly complete protection against HIV infection with just a single administration every six months. The injection, known chemically as lenacapavir and to be marketed as Yeztugo, has been hailed as the closest thing the field has ever had to a vaccine — a groundbreaking intervention that, if rolled out properly, could bring a 45-year-old pandemic to heel.
-
1 week ago |
statnews.com | Ed Silverman
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is already upon us. After all, we have made it this far, so we have decided to hang on for another couple of days. And why not? Given the likely alternatives, this seems to be a reasonable decision. To make the time fly, we are firing up the trusted coffee kettle and brewing another cup of stimulation. Our choice today is honey almond crunch. Can you guess what gives it the crunch?
Pharmalittle: We're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more
1 week ago |
statnews.com | Ed Silverman
Top of the morning to you. Unfortunately, soggy gray skies are enveloping the placid Pharmalot campus, but our spirits remain decidedly sunny, nonetheless. Why? We will trot out a bit of wisdom from the dearly departed Morning Mayor, who taught us that “every new day should be unwrapped like a precious gift.” While you tug on the ribbon, we will fire up the antiquated coffee kettle to brew another cup of stimulation. Please feel free to join us.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 5K
- Tweets
- 282
- DMs Open
- No
FDA scolds Merz over ‘misleading’ Instagram posts featuring interior designer Nate Berkus.. https://t.co/1yetrqOj68… #pharma #FDA #botox #wrinkles #Instagram
Student group that ranked med schools over industry conflicts votes to accept pharma funding.. https://t.co/Oy0tDXJaYA #pharma #medicine #MedicalEducation #medschool #conflicts
““The whole purpose of biosimilars was to introduce competition into the marketplace," said study author Ben Rome. "...The fact that it’s so hard to find savings consistently is disappointing." https://t.co/2VZjM2l1NL #pharma #biotech #biologics #biosimilars #medicines